Please use this identifier to cite or link to this item:
|Title:||Melanoma vaccines: developments over the past 10 years.|
|Authors:||Klein, Oliver;Schmidt, Christopher;Knights, Ashley J;Davis, Ian D;Chen, Weisan;Cebon, Jonathan S|
|Affiliation:||Ludwig Institute for Cancer Research, Austin Branch, Austin Hospital, Studley Road, Heidelberg, Victoria, 3084, Australia.|
|Citation:||Expert Review of Vaccines; 10(6): 853-73|
|Abstract:||Decades of preclinical evaluation and clinical trials into melanoma vaccines have yielded spectacular progress in our understanding of melanoma antigens and the immune mechanisms of tumor rejection. Key insights and the results of their clinical evaluation are reviewed in this article. Unfortunately, durable clinical benefit following vaccination remains uncommon. Two recent clinical advances that will impact on melanoma vaccine development are trials with inhibitors of CTLA-4 and oncogenic BRAF. Long-term therapeutic control of melanoma will require integration of specific active immunotherapy with these emerging successful therapies from the disparate fields of immune regulation and signal transduction.|
|Internal ID Number:||21692705|
Cancer Vaccines.administration & dosage.immunology
Clinical Trials as Topic
Proto-Oncogene Proteins B-raf.antagonists & inhibitors.immunology
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.